In this study, a special imaging test called ⁶⁸Ga-DOTATATE PET/CT is done before the third injection of ¹⁷⁷Lu-oxodotreotide. A PET/CT scan combines two types of scans to show where the tumor is in the body and how active it is. Treatment is given first, and then scans are repeated during follow-up to watch for any signs that the tumor is growing again. The study looks at how the scan results relate to the course of the disease over time.

The medicine being studied may also be listed as edotreotide in some products, and the imaging agent used for the scan is ⁶⁸Ga-edotreotide. The trial focuses on patients with well-differentiated grade 2 disease, which means the tumor cells still look somewhat like normal cells under a microscope, but the cancer can still grow and spread.

The purpose of this study is to evaluate the effectiveness of combining multiple PET (Positron Emission Tomography) scans into a single imaging session for detecting and determining the stage of these cancers. This approach, called multiplexed imaging, will be compared to traditional single-substance scanning methods.

During the study, participants will receive injections of two different imaging substances through their veins and undergo scanning procedures. The imaging substances are radioactive tracers that help create detailed pictures of areas where cancer might be present in the body. The safety of this combined approach will be monitored, and the quality of the resulting images will be evaluated to determine if this new method provides accurate information about the cancer’s location and extent.

The treatment involves receiving either Lutathera infusions together with Sandostatin LAR injections, or only Sandostatin LAR injections. Lutathera contains a radioactive substance that specifically targets tumor cells. During Lutathera treatment, patients will also receive an amino acid solution called LysaKare to protect the kidneys. To manage potential side effects, patients may receive anti-nausea medications.

The study will monitor how the disease responds to treatment through regular medical examinations and imaging tests. Doctors will track any changes in tumor size and assess how patients feel during the treatment. The study will continue for several years to determine the long-term effects of both treatments.

The purpose of this research is to evaluate how well tarlatamab works compared to standard chemotherapy treatments in treating this type of cancer. The study will measure how long patients survive after receiving treatment. The medication will be given through an infusion into a vein.

During the study, doctors will monitor patients’ response to treatment using imaging scans and blood tests. They will also track any side effects that occur and evaluate patients’ quality of life using questionnaires. The study is expected to last for approximately 24 months per patient.

The purpose of the study is to evaluate how well this combination treatment works in patients whose cancers have progressed or become resistant after at least one standard treatment. The study will involve patients receiving the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 24 weeks, during which the effectiveness and safety of the treatment will be closely monitored. Patients will be grouped into different cohorts based on their specific type of cancer, and the study will assess various outcomes, such as the rate of cancer progression and overall survival.

Throughout the study, researchers will collect data to understand how the treatment affects the different types of rare cancers. The goal is to determine if the combination of Domvanalimab and Zimberelimab can provide a new and effective treatment option for patients with these challenging conditions. The study is part of a larger effort to explore innovative therapies for rare cancers, which often have limited treatment options. By participating in this trial, researchers hope to gather valuable information that could lead to improved care for patients with these rare and advanced cancers.

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

The purpose of this study is to determine whether it is possible to perform both imaging methods at the same time to better understand how tumors use energy. During the study, participants will receive two different injectable substances: hyperpolarized [1-13C]pyruvate and Fluor-18-FDG. Both substances will be given through an intravenous injection, and then special images will be taken using a combined PET/MR scanner.

This research will help doctors better understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer. The imaging procedure will be performed once for each participant, and the total dose of each substance has been carefully calculated to ensure safety.

Participants in the study will receive a combination of cabozantinib and lanreotide over a period of up to 24 months. The study will monitor how well patients tolerate the treatment and how the tumors respond to the medication. The trial aims to gather information on the safety of the treatment and its ability to control the growth of the tumors. Additionally, researchers will explore certain biological markers that might help predict how well the treatment works or how safe it is for patients.

The study is divided into different stages, with the initial stage focusing on assessing the safety and tolerability of the treatment. Subsequent stages will continue to evaluate safety while also looking at how effective the treatment is in terms of reducing tumor size or slowing its growth. The trial will also consider the overall survival and progression-free survival of participants, which refers to the length of time patients live without the disease getting worse. This research is important for understanding how these medications can be used to treat neuroendocrine tumors more effectively.

The purpose of the study is to explore the effects of delivering the treatment directly into the liver through a method called intra-arterial hepatic infusion. This approach is being tested in patients whose cancer has spread mainly to the liver. During the study, participants will receive the treatment and undergo imaging scans to assess how well the treatment is working. The study will also monitor the safety of the treatment and its effects on other organs like the kidneys and spleen.

Participants in the study will receive up to five cycles of the treatment, with the possibility of receiving a placebo in some cases. The study aims to gather information on how the treatment affects the tumors and the body, providing valuable insights into its potential benefits and risks for patients with GEP-NETs.

The purpose of the study is to determine if RYZ101 can improve the condition of patients compared to the standard treatments. The study is divided into two parts. In the first part, the focus is on finding the right dose of RYZ101 and assessing its safety and how well it is tolerated by patients. In the second part, the study aims to see if RYZ101 can help patients live longer without their disease getting worse, compared to those receiving standard treatments. The study involves taking the medication either by mouth, as in the case of Everolimus and Sunitinib, or through injections, as with Octreotide and Lanreotide.

Participants in the study will receive either RYZ101 or one of the standard treatments, and their progress will be monitored over time. The study will look at various outcomes, including how long patients live without their disease worsening and any side effects they may experience. This research is important for finding better ways to treat GEP-NETs and improving the quality of life for those affected by this condition.

Participants in the study will receive either Lutathera in combination with supportive care or a higher dose of Sandostatin LAR. Lutathera is administered through an intravenous infusion, which means it is given directly into a vein, while Sandostatin LAR is given as an intramuscular injection, meaning it is injected into a muscle. The study will also involve the use of a solution called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride, to help protect the kidneys during treatment. The trial will follow participants over a period to observe the time it takes for the disease to progress or for any other significant health changes to occur.

The study is designed to be open-label, meaning both the participants and the researchers know which treatment is being administered. It is a randomized trial, which means participants are randomly assigned to receive either Lutathera or the higher dose of Sandostatin LAR. The trial will take place across multiple centers, allowing for a diverse group of participants. The ultimate goal is to gather information that could lead to improved treatment options for patients with advanced GEP-NETs.

The purpose of the study is to determine if treatment with 177Lu-Edotreotide is more effective at slowing down tumor growth compared to everolimus in patients whose tumors cannot be removed by surgery and continue to grow. During the study, patients will receive either 177Lu-Edotreotide through an intravenous infusion along with a protective amino acid solution, or they will take everolimus tablets daily.

The treatment with 177Lu-Edotreotide, known as Peptide Receptor Radionuclide Therapy (PRRT), involves giving a radioactive substance that specifically targets tumor cells. Patients receiving this treatment will also get an Arginine-Lysine solution through an intravenous line to protect their kidneys. Those in the everolimus group will take tablets that work by blocking signals that cancer cells use to grow.

The purpose of the study is to evaluate how safe Lutathera is for use in adolescents and to understand how the body absorbs the radiation from this treatment. Another medication used in the study is called LysaKare, which contains L-lysine hydrochloride and L-arginine hydrochloride. These are amino acids that help protect the kidneys during the treatment. The study will involve monitoring the participants over a period of time to see how their bodies respond to the treatment and to check for any side effects.

Participants in the study will receive the treatment over a period of up to 36 months. During this time, doctors will closely monitor the participants’ health and the effects of the treatment. The study aims to gather information on the safety and effectiveness of Lutathera in treating these specific types of tumors in adolescents. This information will help in understanding how well the treatment works and its potential side effects.

The study includes several standard cancer treatments that may be used as comparison: Everolimus, Temozolomide, Capecitabine, Oxaliplatin, and Fluorouracil. Some patients will also receive supportive medications like Calcium Folinate and an amino acid solution to protect their kidneys during treatment. The purpose is to determine if the radioactive treatment is more effective than current standard treatments for these types of tumors.

During the study, patients will be randomly assigned to receive either the radioactive treatment or one of the standard treatments. The doctors will monitor how well the treatments work by taking regular scans and checking patients’ overall health. They will also track how the treatments affect patients’ quality of life using questionnaires.

The purpose of the study is to determine if CAM2029 is more effective than the other treatments in delaying the progression of the tumors. Participants in the study will receive one of these treatments and will be monitored over time to see how their condition changes. The study will involve regular check-ups and assessments to track the health and response of the participants to the treatment.

Throughout the study, participants will receive injections of the assigned treatment and may also receive a placebo. The study will last for a period of time, during which the health and quality of life of the participants will be closely observed. The goal is to gather information that could lead to better treatment options for people with GEP-NET in the future.

The purpose of the study is to understand the benefits of continuing treatment with somatostatin analogues (a type of medication that helps control hormone-related symptoms) when the disease progresses. The study is divided into two parts: one part looks at the effects of continuing or stopping these medications when patients start a second-line treatment called PRRT (Peptide Receptor Radionuclide Therapy), and the other part examines the effects when patients start a different type of second-line treatment known as targeted therapy. The study aims to see if continuing these medications can help delay the worsening of the disease and improve the quality of life for patients.

Participants in the study will receive either the medication or a placebo, and their progress will be monitored over time. The study will assess how long patients can live without their disease getting worse and how long it takes for their overall health to decline. The study will also look at the overall survival rates, response to treatment, quality of life, and any side effects experienced by the participants. This information will help determine the best approach to managing neuroendocrine tumors when the disease progresses.